Journal Information
Vol. 13. Issue 3.
Pages 383-389 (May - June 2007)
Share
Share
Download PDF
More article options
Vol. 13. Issue 3.
Pages 383-389 (May - June 2007)
Full text access
Tabaco e morfologia: Doenças pulmonares
Tobacco and morphology: Pulmonary diseases
Visits
1065
Lina Carvalho
Professora de Anatomia Patológica. Faculdade de Medicina da Universidade de Coimbra
This item has received
Article information
Abstract
Bibliography
Download PDF
Statistics
Resumo

O tabaco está implicado na carcinogénese multiorgânica, com identificação de mais de cinquenta substâncias carcinogénicas que induzem mutações, alterando o ciclo celular, a resposta auto-imune e a regulação endócrina. É um dos nove factores identificados responsáveis por um terço de mortes por neoplasias malignas juntamente com erros dietéticos, obesidade, sedentarismo, consumo de álcool, promiscuidade sexual, toxicodependência e poluição ambiental geral e limitada. Está implicado nas doenças cardiovasculares que representam a primeira causa de morte nos países civilizados e, no aparelho respiratório, é o factor principal para o desenvolvimento de DPOC (doença pulmonar obstrutiva crónica), RB-ILD (bronquiolite respiratória e doença pulmonar intersticial), DIP (pneumonia intersticial descamativa), bronquiolite e fibrose intersticial bronquiolocêntrica, histiocitose de células de Langerhans, pneumonia eosinofílica, sarcoidose, metaplasia epidermóide do epitélio respiratório e carcinoma bronco-pulmonar. O estado inflamatório crónico sistémico induzido pelo tabaco constitui a base de desenvolvimento de alterações genéticas também dependentes dos contaminantes do tabaco.

Palavras-chave:
Tabaco
morfologia pulmonar
Abstract

Tobacco is implicated in multisystemic carcinogenesis through more than fifty identified carcinogenic metabolites that produce mutations responsible for alterations in cell cycle, immune response and endocrine regulation. Is one of nine risk factors identified in one third of cancer deaths together with obesity, sedentary, alcohol consumption, sexual promiscuity, drug addiction, and open and closed air contamination. Answering for cardiovascular diseases as the first cause of death in civilized world, tobacco is also pointed as the major factor implicated in the development of COPD (chronic obstructive pulmonary disease), RB-ILD (respiratory bronchiolitis and interstitial lung disease), DIP (desquamative interstitial pneumonia), bronchiolitis and bronchiolocentric interstitial fibrosis, Langerhans cells histiocytosis, eosinophilic pneumonia, sarcoidosis, epidermoid metaplasia in respiratory epithelium and lung cancer. The chronic tobacco induced inflammatory state is the basis for the acquisition of genetic alterations dependent on the tobacco contaminants.

Key-words:
Tobacco
lung morphology
Full text is only aviable in PDF
Bibliografia
[1.]
G.C. Kabat.
Fifty years' experience of reduced-tar cigarettes: what do we know about their health effects?.
Inhalation Toxicology, 15 (2003), pp. 1059-1102
[2.]
E. Wynder, E. Graham.
Tobacco smoking as a possible etiologic factor in bronchiogenic carcinoma.
Bulletin of the World Health Organization, 83 (2005), pp. 146-153
[3.]
N. Godtfredson, E. Prescott, M. Osler.
Effect of smoking reduction on lung cancer risk.
JAMA, 294 (2005), pp. 1505-1510
[4.]
C. Haiman, D. Stram, L. Wilkens, M. Pike, L. Colonel, B. Henderson, L. Marchand.
Ethnic and racial differences in smoking-related risk of lung cancer.
N Engl J Med, 354 (2006), pp. 333-342
[5.]
F. Paula, F. Gamito, L. Ferreira.
Importância da nova classificação das pneumonias intersticiais idiopáticas – A propósito de um caso.
Rev Port Pneumol, 7 (2001), pp. 49-56
[6.]
W.D. Travis, T.E. King, E.D. Bateman, et al.
ATS/ERS International Multidisciplinary Consensus Classification of Idiopathic Interstitial Pneumonia.
Am J Respir Crit Care Med, 165 (2002), pp. 277-3304
[7.]
P.A. Kirkham, G. Spooner, C. Foulkes-Jones, R. Calvez.
Cigarette smoke triggers macrophage adhesion and activation: role of lipid peroxidation products and scavenger receptor.
Free Radical Biology & medicine, 35 (2003), pp. 697-710
[8.]
M. Montano, C. Beccerril, V. Ruiz, C. Ramos, R.H. Sansores, G. Gonzalez-Avila.
Matrix metalloproteinases activity in COPD associated with wood smoke.
Chest, 125 (2004), pp. 466-472
[9.]
S. Nobukuni, K. Watanabe, J. Inoue, F.Q. Wen, N. Tamaru, M. Yoshida.
Cigarette smoke inhibits the growth of lung fibroblasts from patients with pulmonary emphysema.
Respirology, 7 (2002), pp. 217-223
[10.]
W. Gan, P. Man, D. Sin.
The interactions between cigarette smoking and reduced lung function on systemic inflammation.
Chest, 127 (2005), pp. 558-564
[11.]
A.J. Frew.
Advances in environmental and occupational disorders.
Journal of Allergy & Clinical Immunology, 111 (2003), pp. S824-S828
[12.]
A. Hjern, A. Hedberg, B. Haglung, M. Rosen.
Does tobacco smoke prevent atopic disorders?.
Clinical & Experimental Allergy, 31 (2001), pp. 908-914
[13.]
P. Canessa, L. Prattico, L. Bancalari, F. Fedeli, B. Bacigalupi, S. Silvano.
Respiratory bronchiolitis associated with interstitial lung disease.
Monaldi Arch Chest Dis, 61 (2004), pp. 174-176
[14.]
S. Kamholz.
Pulmonary and cardiovascular consequences of smoking.
Clin Occup Environ Med, 5 (2006), pp. 157-171
[15.]
E. Grossi, G. Polrtti, V. Poletti.
Acute eosinopholic pneumonia with respiratory failure: a case likely triggered by cigarette smoking.
Monaldi Arch Chest Dis, 61 (2004), pp. 58-61
[16.]
H. Terasaki, K. Fujimoto, N. Muller, J. Sadohara, M. Uchida, T. Koga, H. Aizawa, N. Havabuchi.
Pulmonary sarcoidosis: comparison of findings of inspiratory and expiratory high-resolution CT and pulmonary function tests between smokers and nonsmokers.
Am J Roentgenol, 185 (2005), pp. 333-338
[17.]
D. Sin, S. Man, A. McWilliams, S. Lam.
Progression of airway dysplasia and C-reactive protein in smokers at high risk of lung cancer.
Am J Respir Crit Care Med, 173 (2006), pp. 535-539
[18.]
A. Pasic, E. Vliet, R. Breuer, E. Risse, P. Snijders, P. Postmus, T. Sutedja.
Smoking behaviour does not influence the natural course of pre-invasive lesions in bronchial mucosa.
Lung Cancer, 45 (2004), pp. 153-154
[19.]
K.R. Smith, D.L. Uueminami, U.P. Kodavanti, J.D. Crapo, L.Y. Chang, K.E. Pinkerton.
Inhibition of tobacco smoke-induced lung inflammation by catalytic antioxidant.
Free Radical Biology & Medicine, 33 (2002), pp. 1106-1114
[20.]
S.S. Hecht.
Recent studies on mechanisms of bioactivation and detoxification of 4-(methylnitrosamino(-1-(3- pyridyl)-1-butanone (NNK), a tobacco-specific lung carcinogen.
Critical Reviews in Toxicology, 26 (1996), pp. 163-181
[21.]
K.A. West, I.R. Linnoila, S.A. BelinsKy, C.C. Harris, P.A. Dennis.
Tobacco carcinogen-induced cellular transformation increases activation of the phosphatidyllinositol 3'-Kinase/Akt pathway in vitro and in vivo.
Cancer Research, 64 (2004), pp. 446-451
[22.]
H. Adami, D. Hunter, D. Trichopoulos.
Textbook of Cancer Epidemiology.
Oxford University Press, (2002),
[23.]
T. Dutu, S. Michiels, P. Fouret, F. Penault-Llorca, P. Validire, S. Benhamous, E. Taranchon, L. Morat, D. Grunenwald, T. Le Chevalier, L. Sabatier, L. Soria.
Differential expression of biomarkers in lung adenocarcinoma: a comparative study between smokers and never-smokers.
Ann Oncol, 16 (2005), pp. 1906-1914
[24.]
M.G. Traber, A. Vliet, A.Z. Reznick, C.E. Cross.
Tobacco-related diseases.
Clinics in Chest Medicine, 21 (2000), pp. 173-187
[25.]
J.P. Cooke, H. Bitterman.
Nicotine and angiogenesis: a new paradigm for tobacco-related diseases.
Annals of, 36 (2004), pp. 33-40
[26.]
S.S. Hecht.
Cigarette smoking and lung cancer: chemical mechanisms and approaches to prevention.
Lancet Oncology, 3 (2002), pp. 461-469
[27.]
H. Kuper, H. Adami, P. Boffetta.
Tobacco use, cancer causation and public health impact.
Journal of Internal Medicine, 251 (2002), pp. 455-466
[28.]
Q. Wei, L. Cheng, C.I. Amos, L.E. Wang, Z. Guo, W.K. Hong, M.R. Spitz.
Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk: a molecular epidemiologic study.
Journal of National Cancer Institute, 92 (2000), pp. 1764-1772
[29.]
H. Kuper, H.O. Adami, P. Boffetta.
Tobacco use, cancer causation and public health impact.
J Intern Med, 251 (2002), pp. 455-466
[30.]
H.M. Schuller, B.A. Jull, B.J. Sheppard, H.K. Plummer.
Interaction of tobacco-specific toxicants with the neuronal alpha(7) nicotinic acetylcholine receptor and its associated mitogenic signal transduction pathway: potential role in lung carcinogenesis and pediatric lung disorders.
European Journal of Pharmacology, 393 (2000), pp. 265-277
[31.]
J. Wisnivesky, J. Szwarcberg, T. McGinn.
Lung cancer, screening, counselling, and treating long-term smokers.
Geriatrics, 57 (2002), pp. 28-32
[32.]
Y. Garces, J. Hays.
Tobacco dependence: why should an oncologist care?.
Journal of Clinical Oncology, 21 (2003), pp. 1884-1886
[33.]
G. Colditz, C. Stein.
Handbook of Cancer Risk Assessment and Prevention.
Jones and Bartlett Publishers, (2003),
[34.]
S. Curry, T. Byers, M. Hewitt.
Cancer Prevention and Early Detection.
The National Academies Press, (2003),
[35.]
J. Westmaas, T. Brandon.
Reducing risk in smokers.
Curr Opin Pulm Med, 10 (2004), pp. 284-288
[36.]
J. Mulshine, D. Sullivan.
Lung cancer screening.
N Engl L Med, 352 (2005), pp. 2714-2720
[37.]
W. Blot, J. McLaughlin.
Are women more susceptible to lung cancer?.
Journal of the National Cancer Institute, 96 (2004), pp. 812-813
[38.]
H. Kawai, A. Tada, M. Kawahara, K. Nakai, H. Maeda, R. Saitou, F. Iwami, K. Ishikawa, S. Fukai, H. Komatsu.
Smoking history before surgery and prognosis in patients with stage IA non-small-cell lung cancer – a multicenter study.
Lung Cancer, 49 (2005), pp. 63-70
Copyright © 2007. Sociedade Portuguesa de Pneumologia
Download PDF
Pulmonology
Article options
Tools

Are you a health professional able to prescribe or dispense drugs?